Article Text

Download PDFPDF
The end of the line for the Surviving Sepsis Campaign, but not for early goal-directed therapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests EPR reports that in the past two years he has consulted for Aggenix, Esai Pharmaceuticals and Astra Zeneca. PAN reports no competing interests.

  • Provenance and peer review Not commissioned; not externally peer reviewed.